ORPN News and Press, Bioblast Pharma Ltd.

It has only been a few months since my first Seelos article ( SEEL ), but the company has been negotiating two deals to expand its pipeline and areas of study. The first deal was made in February with Bioblast Pharma ( ORPN ) concerning their mutant protein stabilization solution called Treh...

Tel Aviv, Israel, March 06, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced the effectiveness of an eight to one reverse split of its share capital. As previously reported, the reverse split was approv...

Gainers:  Art's-Way Manufacturing (NASDAQ: ARTW ) +68% . Riot Blockchain (NASDAQ: RIOT ) +47% . Bioblast Pharma (NASDAQ: ORPN ) +45% . Ideanomics (NASDAQ: IDEX ) +26% . Kraton Corporation (NYSE: KRA ) +25% . Superior Energy Services (NYSE: SPN ) +23% . Identiv (NASDAQ: INVE ) +...

Thinly traded nano cap Bioblast Pharma ( ORPN +64% ) is up a healthy 31x surge in volume on the heels of the sale of its Trehalose program to Seelos Therapeutics ( SEEL -3.3% ) for up to $20.5M. More news on: Bio Blast Pharma, Seelos Therapeutics Inc, Healthcare stocks news, Stocks o...

CORAL GABLES, FL / ACCESSWIRE / February 19, 2019 / The success of healthcare stock market is based on whether or not companies in the healthcare industry have the ability to meet the growing demands of consumers. It's no longer a question of simply creating treatment options and offering ...

Bioblast Pharma (NASDAQ: ORPN ) +36%  on announcing sale of Trehalose clinical development programs to Seelos Therapeutics. More news on: Bio Blast Pharma, Sky Solar Holdings, Intercept Pharmaceuticals, Stocks on the move, Read more ...

Diversifies Seelos’ pipeline in rare diseases Collaborates with Team Sanfilippo Foundation in development of Trehalose in Sanfilippo syndrome NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announc...

Unconditional payment of $3.5 million Contingent payment of up to additional $17 million plus royalties Seelos to receive rights also to the Trehalose for Sanfilippo Syndrome Program Tel Aviv, Israel, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. ( Nasdaq: ORPN), ...

Tel Aviv, Israel, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN) (“Bioblast”), a clinical-stage, orphan disease-focused biotechnology company, and Team Sanfilippo (“TSF”), a nonprofit medical research foundation founded by parents of chil...

TEL AVIV, Israel and NEW YORK, July 26, 2018 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN) is providing an update on business development activities as well as notice of an organization change that affects members of the board and management. As previously announced, the Company...